Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8096180.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).
Medical subject headings
- Heart Diseases
- Mortality
- Myocardial Infarction